The Phase II clinical study investigated the efficacy and tolerability of OptiNose's novel, intranasal sumatriptan product for treating migraine. The results showed high efficacy, with pain-free rates at two hours being 54% for the 10mg dose and 57% for the 20mg dose.
A Phase II clinical study found that OptiNose's novel device delivered significant reductions in polyp size and improvements in symptoms, including facial pressure, nasal obstruction, and sense of smell. The treatment resulted in a substantial proportion of patients experiencing complete removal of polyps.
Patients in the active treatment group experienced significant improvements in nasal symptoms, sense of smell, and a reduction in nasal swelling. The study showed a highly significant improvement to a normal state in the nasal mucosa, with peak nasal inspiratory flow and rhinosinusitis outcome measures also significantly improved.
A Phase II trial of OptiNose's novel nasal drug delivery device showed a significant reduction in nasal polyp size and associated symptoms, with almost 80% of patients experiencing overall improvement. The treatment achieved a 57.4% reduction in polyp size and improved sense of smell, nasal obstruction, and nasal comfort.